The Randomized Phase 2 ARC-9 Study of Etrumadenant-Based Therapy vs Regorafenib in Patients with Previously Treated Metastatic Colorectal Cancer
Michael Cecchini·Zev A. Wainberg·Soohyeon Lee·Keun-Wook Lee·Scott Kopetz·Jonathan D. Mizrahi·Yong Sang Hong·François Ghiringhelli·Antoine Italiano·David Tougeron·Brandon Beagle·Mathew Boakye·Tingting Zhao·Vivek Khemka·S. W. Han
EZFB significantly improved survival outcomes compared with regorafenib in patients with mCRC as a third-line treatment, with a manageable safety profile. Further investigation is warranted, given the clinically meaningful improvements in progression-free survival and overall survival.